Audio Recap: IDWeek/HIV Glasgow 2022
Key HIV Studies Influencing My Practice Following IDWeek and HIV Glasgow 2022—Audio Recap

Released: December 05, 2022

Chloe Orkin
Chloe Orkin, MBChB, FRCP, MD
Babafemi Taiwo
Babafemi Taiwo, MBBS

Activity

Progress
1
Course Completed

In this episode, Chloe Orkin, MBChB, FRCP, MD, and Babafemi Taiwo, MBBS, discuss new HIV data presented at IDWeek and HIV Glasgow 2022, including

  • Prevention strategies
    • Updated data from HPTN 083 evaluating LA CAB for PrEP in men who have sex with men and transgender women
    • Data on awareness and use of PrEP among cisgender women in the United States
  • LA therapies
    • Data from an expanded multivariable analysis of factors associated with virologic failure of LA CAB + RPV
    • Data from the OPERA cohort on outcomes during the first year of real-world LA CAB + RPV use in the United States
    • Data from the CARLOS cohort on 6-month outcomes of real-world LA CAB + RPV use in Germany
    • Safety, efficacy, and adherence data from the CARISEL phase IIIb implementation study of LA CAB + RPV use in Europe
    • Week 52 efficacy, safety, and lenacapavir resistance data from the CAPELLA trial
  • Investigational agents
    • Post hoc analysis of P011 evaluating dose-dependent islatravir effect on lymphocytes
    • Modeling and simulation study to identify optimal islatravir dosing for clinical development